Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $41.00

Castle Biosciences (NASDAQ:CSTL) had its target price raised by Robert W. Baird from $39.00 to $41.00 in a research report released on Monday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other equities research analysts also recently commented on CSTL. Weiss Ratings restated a “sell (d-)” rating on shares of Castle Biosciences in a report on Thursday, October 29th. KeyCorp upped their target price on Castle Biosciences from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. Mizuho initiated coverage on Castle Biosciences in a report on Thursday, October 29th. They issued an “outperform” rating and a $60.00 target price on the stock. BTIG Research lifted their price target on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.50.

Castle Biosciences Stock Performance

Shares of CSTL opened at $33.99 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.28 and a quick ratio of 5.12. The stock has a 50-day moving average of $34.30 and a 200-day moving average of $28.42. The company has a market cap of $1.05 billion, a PE ratio of -44.14 and a beta of 1.00. Castle Biosciences has a one year low of $17.72 and a one year high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.22. Castle Biosciences had a negative return on equity of 4.89% and a negative net margin of 6.10%. The business had revenue of $101.95 million during the quarter, compared to analyst estimates of $92.76 million. On average, equities research analysts predict that Castle Biosciences will post -0.83 EPS for the current fiscal year.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, COO Kristen Oelschlager sold 12,384 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $34.42, for a total transaction of $426,257.28. Following the completion of the sale, the chief operating officer directly owned 72,649 shares of the company’s stock, valued at approximately $2,500,578.58. The trade was a 14.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Derek J. Maetzold sold 12,428 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $33.20, for a total value of $412,609.60. Following the sale, the insider directly owned 21,479 shares of the company’s stock, valued at $713,102.80. This represents a 36.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 126,184 shares of company stock worth $4,324,506. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Castle Biosciences during the second quarter worth $78,513,000. Jefferies Financial Group Inc. bought a new stake in shares of Castle Biosciences in the 2nd quarter worth $15,440,000. AIGH Capital Management LLC bought a new stake in shares of Castle Biosciences in the 2nd quarter worth $13,001,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Castle Biosciences in the second quarter valued at about $7,912,000. Finally, Advisors Capital Management LLC purchased a new stake in shares of Castle Biosciences in the second quarter valued at about $5,681,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Trending Headlines about Castle Biosciences

Here are a few of the latest headlines about CSTL:

• Positive Sentiment: Castle said analyses to be presented at dermatology conferences indicate DecisionDx-Melanoma can identify higher-risk patients among people with thin melanomas and provide individualized five-year recurrence-risk estimates for stage I–III melanoma. The findings may reinforce the test’s clinical value and potential to inform patient monitoring, though the announcement describes data presentations rather than new commercial results. Article: DecisionDx-Melanoma Data at SDPA and Dermato-Onco2026
• Positive Sentiment: Analyst sentiment is favorable: BTIG raised its price target to $52 and maintained a Buy rating, while Canaccord Genuity also issued a Buy rating. These ratings may support investor confidence, but targets are opinions, not guarantees. Article: BTIG Research rating and price target Article: Canaccord Genuity Buy rating
• Neutral Sentiment: Castle’s management is scheduled to present at the Piper Sandler Healthcare Conference on Dec. 2. The appearance may provide an opportunity for updates, but no new business or financial information was announced. Article: Castle Biosciences to Present at the Piper Sandler Conference

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.